United States Patent 7,468,363: Claim Scope, Exclusivity, Litigation and Lenalidomide Patent Landscape

US Patent 7,468,363 protects selected methods of using lenalidomide, not lenalidomide itself. Its core limitation is administration of approximately 5 to 50 mg per day for specified hematologic malignancies, solid tumors, amyloidosis, and cutaneous lymphomas. Dependent claims narrow the methods by requiring combination therapy, oral delivery, capsules or tablets, lower dosing, and a 21-days-on/7-days-off cycle.

The patent is associated with Celgene’s Revlimid franchise. Its nominal expiration date is June 8, 2027, subject to the patent’s recorded term adjustments and legal status. The patent’s practical value is concentrated in method-of-use protection and infringement risk for products labeled or marketed for the covered indications and dosing regimens.

What drug and therapeutic uses does US Patent 7,468,363 cover?

The claimed compound is lenalidomide, also known as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione. The claims also cover pharmaceutically acceptable salts.

The patent does not claim:

The basic chemical composition of lenalidomide;
A new crystalline form;
A specific excipient system;
A manufacturing process;
A capsule shell;
A tablet composition; or
A broad genus of immunomodulatory compounds.

Its claims are directed to treating named diseases with a defined daily dose and, in several claims, specified companion drugs.

Claim group	Disease or use	Dose	Combination requirement
1	Non-Hodgkin’s lymphoma	About 5-50 mg/day	None
2	Ovarian cancer	About 5-50 mg/day	Cisplatin
3	Pancreatic cancer	About 5-50 mg/day	Gemcitabine
4	Renal cancer	About 5-50 mg/day	None
5	Amyloidosis	About 5-50 mg/day	None
6	Cutaneous T-cell lymphoma	About 5-50 mg/day	None
7	Non-Hodgkin’s lymphoma	About 5-50 mg/day	Rituximab
8	Ovarian cancer	About 5-50 mg/day	Topotecan
9	Non-Hodgkin’s lymphoma	About 5-50 mg/day	Fludarabine
10	Cutaneous B-cell lymphoma	About 5-50 mg/day	None
11	Diffuse large B-cell lymphoma	About 5-50 mg/day	None
16	Amyloidosis	About 5-50 mg/day	Melphalan or dexamethasone
17	Non-Hodgkin’s lymphoma	About 5-50 mg/day	Protein kinase inhibitor

Claims 12 and 13 extend claims 5, 6, 10, and 11 by adding rituximab or fludarabine. Claim 14 specifies the free lenalidomide compound, while claim 15 covers a pharmaceutically acceptable salt.

The references in claims 3, 7, and 9 that omit the "1-oxo" wording appear to be chemical nomenclature inconsistencies in the claim set. They should be assessed against the patent’s specification, prosecution history, and claim-construction record rather than treated automatically as separate chemical species.

How do the dose and regimen limitations affect infringement risk?

The broadest dose limitation is "from about 5 to about 50 mg per day." The term "about" introduces a range-construction issue. It generally does not eliminate the need to prove that the accused regimen falls within a reasonably understood range surrounding 5 to 50 mg per day.

Claim 20 narrows the dose to approximately 5 to 25 mg per day. Claims 21 through 24 add cyclic administration:

A cycle of four to six weeks;
Twenty-one days of treatment followed by seven days of rest; and
Approximately 5 to 25 mg per day for 21 days followed by 7 days of rest in a 28-day cycle.

A generic product containing lenalidomide may avoid direct infringement of a method claim if it is sold with a label that omits the patented indication or regimen. That protection is limited where the product’s label, promotional materials, distribution controls, clinical support, or other evidence encourage the claimed use. Induced infringement under 35 U.S.C. § 271(b) can arise from affirmative encouragement even when the manufacturer does not administer the drug itself.

A product administered at 25 mg on days 1 through 21 of a 28-day cycle presents a stronger overlap with claims 20 and 24 than a product labeled only for continuous daily administration. The specific disease indication remains essential. A lymphoma label is materially more relevant than a multiple-myeloma-only label unless the approved or promoted lymphoma use falls within the patent claims.

Which claims are strongest from a commercial enforcement perspective?

The strongest commercial claims are likely the claims that combine a commercially established lenalidomide regimen with a recognizable disease population.

Claims 1, 10 and 11: single-agent lymphoma methods

These claims cover:

Non-Hodgkin’s lymphoma;
Cutaneous B-cell lymphoma; and
Diffuse large B-cell lymphoma.

They do not require a second drug, which makes them easier to practice but potentially more vulnerable to prior-art challenges based on earlier lenalidomide clinical studies, thalidomide analog research, or oncology treatment disclosures.

Claims 7, 9, 12, 13 and 17: combination regimens

Combination claims require proof that the patient receives lenalidomide together with the specified companion therapy. They may be harder to infringe accidentally because the accused treatment must include rituximab, fludarabine, a protein kinase inhibitor, or another named agent.

They can be commercially important when a treatment protocol, clinical pathway, or label expressly recommends the combination. Claim 17 is broader than the claims naming rituximab or fludarabine because it covers a "protein kinase inhibitor," but that term may create construction and enablement issues depending on the prosecution history.

Claims 2, 3, 8 and 16: solid-tumor and amyloidosis combinations

These claims cover:

Ovarian cancer with cisplatin;
Pancreatic cancer with gemcitabine;
Ovarian cancer with topotecan; and
Amyloidosis with melphalan or dexamethasone.

Their value depends heavily on actual clinical and regulatory use. A claim covering an unapproved or rarely used indication may have limited direct commercial leverage even if technically valid.

What is the patent’s legal status and expiration date?

US Patent 7,468,363 issued on December 23, 2008. Public patent records identify June 8, 2027, as the nominal expiration date associated with the patent family and applicable US term data. The patent should be distinguished from earlier lenalidomide composition patents and from later patents covering formulations, dosing schedules, risk-management systems, and additional indications.

The patent’s legal value before expiration depends on:

Whether the relevant claim remains enforceable;
Whether maintenance fees were paid;
Whether terminal disclaimers affect the term;
Whether a court has narrowed or invalidated any claim;
Whether the accused product’s label or conduct satisfies the disease, dose, and combination limitations; and
Whether the asserted use is within the approved labeling or is an off-label use.

A patent expiration date does not itself establish that every lenalidomide product can launch on that date. Other unexpired patents may cover the same active ingredient, dosing schedule, indication, manufacturing process, or formulation.

What is the Orange Book status of US Patent 7,468,363?

The FDA Orange Book must be analyzed by product, patent-use code, and listed expiration date. A patent may be relevant to Revlimid without providing broad protection against every generic lenalidomide product.

The key distinction is between:

Patents listed for an approved method of using Revlimid;
Patents covering the active ingredient or product formulation;
Patents covering risk-management or distribution controls; and
Patents covering uses not reflected in the approved labeling.

US Patent 7,468,363 is a method-of-use patent. Its practical Orange Book significance therefore depends on whether the covered lymphoma, amyloidosis, ovarian-cancer, pancreatic-cancer, renal-cancer, or cutaneous-lymphoma use is identified in the FDA listing and associated use code. An Orange Book listing does not expand the patent’s claim scope beyond the actual claim language.

For a generic applicant, a Paragraph IV certification would typically need to address each listed patent that the applicant believes is invalid, unenforceable, or not infringed. A product may use a section viii statement to carve out a patented use only where the FDA-approved labeling can omit that use without including the claimed method.

When does lenalidomide lose exclusivity?

Lenalidomide exclusivity is layered rather than controlled by a single patent.

Protection type	General relevance
Regulatory exclusivity	Depends on the specific Revlimid indication and FDA approval history
Composition patents	Earlier patents protecting lenalidomide or related chemical matter
Method-of-use patents	Includes US 7,468,363 and later indication or regimen patents
Formulation patents	May cover solid oral dosage forms, particle characteristics, or excipients
Risk-management IP	May concern controlled distribution and prescribing systems
Manufacturing patents	May create process or supply-chain barriers
Settlement rights	May control the timing and scope of authorized or licensed generic entry

The commercial entry date is therefore determined by the last enforceable patent and the terms of any settlement agreement, not solely by US 7,468,363. Celgene’s settlements with generic manufacturers produced staggered and sometimes limited launch rights for lenalidomide products. Several companies entered under negotiated licenses before the full expiration of the principal Revlimid patent estate, subject to product, strength, and indication restrictions.

Which companies have challenged Revlimid and lenalidomide patents?

Generic and specialty pharmaceutical companies that have been involved in Revlimid patent challenges or settlements include:

Dr. Reddy’s Laboratories;
Natco Pharma;
Teva Pharmaceuticals;
Cipla;
Zydus Pharmaceuticals;
Sun Pharmaceutical Industries;
Mylan or Viatris-related entities; and
Other abbreviated new drug application sponsors.

The exact litigation posture differs by defendant and patent. Some cases involved Paragraph IV challenges; others ended through settlement, licensing, or authorized-generic arrangements. The existence of a challenge does not establish invalidity. A settlement also does not constitute a judicial determination that the patent is valid or infringed.

What other patents compete with US Patent 7,468,363?

The surrounding lenalidomide estate generally includes four overlapping categories.

Chemical composition patents

These patents protect lenalidomide or related compounds. Their expiration dates are earlier than many later method-of-use patents, but they remain important to the historical exclusivity analysis.

Indication patents

Later patents may cover multiple myeloma, myelodysplastic syndromes, mantle-cell lymphoma, follicular lymphoma, marginal-zone lymphoma, or other disease populations. These claims can remain relevant after a generic removes the indications recited in the 7,468,363 claims.

Dosing and schedule patents

Patents may claim lower-dose regimens, maintenance treatment, treatment cycles, combination schedules, or patient-selection criteria. They create risk even when the generic product uses the same active ingredient and dosage form.

Formulation and manufacturing patents

A capsule or tablet may implicate patents covering excipients, dissolution, particle size, polymorphs, intermediates, impurity control, or manufacturing processes. These patents can affect supply and licensing even when a product label avoids a patented indication.

How does US Patent 7,468,363 compare with a lenalidomide formulation patent?

US 7,468,363 is use-based. It requires proof of:

A qualifying disease;
Administration of lenalidomide;
The claimed dose range; and, for certain claims,
The required companion therapy or regimen.

A formulation patent instead focuses on the product itself, such as a capsule composition, tablet architecture, excipient combination, dissolution profile, or physical form. Formulation claims can be infringed by making, selling, or importing the product regardless of the indication promoted.

The two patent types create different generic strategies. A company may avoid a method-of-use claim through a label carve-out but still infringe a formulation or composition claim. Conversely, a generic may use a noninfringing formulation while facing induced-infringement exposure from a broad oncology label.

What generic launch scenarios arise after a Paragraph IV challenge?

Three principal scenarios apply.

Full-label launch

The generic applicant markets all approved indications. This creates the highest exposure to method-of-use patents, including claims directed to lymphoma or other covered diseases.

Skinny-label launch

The applicant removes patented indications or regimens from the proposed label under a section viii approach. The effectiveness depends on whether the remaining label still encourages the claimed use.

Licensed or authorized launch

The applicant launches under a settlement or license before full patent expiration. The agreement may limit:

Launch date;
Dosage strengths;
Indications;
Distribution channels;
Authorized-generic competition;
Manufacturing sources; and
Volume or supply conditions.

For lenalidomide, launch risk must be assessed across the full patent family and settlement network rather than by analyzing US 7,468,363 in isolation.

Key Takeaways

US 7,468,363 is a lenalidomide method-of-use patent.
Its core dose is approximately 5 to 50 mg per day.
It covers lymphoma, amyloidosis, several solid tumors, and cutaneous lymphomas.
Several claims require combinations with rituximab, fludarabine, cisplatin, gemcitabine, topotecan, melphalan, dexamethasone, or a protein kinase inhibitor.
Claims 20 through 24 protect lower-dose and 21-days-on/7-days-off regimens.
The patent does not broadly claim lenalidomide, a formulation, or a manufacturing process.
The nominal expiration date is June 8, 2027.
Generic exposure depends on the label, promoted indication, dosing regimen, and companion therapy.
Orange Book relevance must be assessed through the specific Revlimid listing and use code.
A launch analysis must include later formulation, dosing, indication, manufacturing, and settlement-related patents.

FAQs About US Patent 7,468,363 and Lenalidomide

Does US Patent 7,468,363 cover all uses of Revlimid?

No. It covers only the claimed diseases, doses, combinations, administration routes, dosage forms, and schedules. It does not provide universal protection for every use of lenalidomide.

Can a generic launch with a lower dose than 5 mg per day?

A regimen materially below the claimed range may avoid literal infringement of the dose limitation, but other patents or theories of infringement may remain relevant. The meaning of "about" must be assessed in context.

Does a 21-days-on/7-days-off regimen fall within the patent?

Yes, claim 24 expressly recites approximately 5 to 25 mg per day for 21 days followed by 7 days of rest in a 28-day cycle.

Are biosimilar rules relevant to lenalidomide?

No. Lenalidomide is a chemically synthesized small-molecule drug. Generic-drug rules under section 505(j), including ANDA and Paragraph IV procedures, are generally more relevant than the biosimilar pathway under the Public Health Service Act.

Does patent expiration eliminate all Revlimid launch barriers?

No. Other patents, FDA requirements, settlement agreements, manufacturing constraints, controlled-distribution obligations, and product-specific Orange Book listings may continue to affect launch timing and commercial exposure.

References

United States Patent and Trademark Office. (2008). US Patent No. 7,468,363, Methods of treating cancer.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Revlimid (lenalidomide) prescribing information.
35 U.S.C. §§ 271, 281-285.
21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2105135	⤷ Start Trial	1590004-6	Sweden	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	C300717	Netherlands	⤷ Start Trial
European Patent Office	2105135	⤷ Start Trial	CA 2015 00006	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,468,363

Summary for Patent: 7,468,363